← back to rankingTHC · Tenet Healthcare Corporation
Medical - Care Facilities · mkt cap $14.1B · calls: Q1 FY2026 vs Q4 FY2025
41.0 conviction · conf-adj 41
conf 2/10 partial
enthusiasm:21.0 · trend:8 · quantifies:0 · impact:0 · under_radar:5 · credibility:0 · business_impact:4 · disruption:0 · commitment:0 · confirmation:3
Enthusiasm latest 7 / prev 5 (rising)
Tenet’s AI story sharpened from Q4 FY2025’s structural-cost framing to Q1 FY2026’s named pilots (ambient scribe, automated discharge summaries, autonomous professional fee coding), back-office automation, and planned agentic workflows—mostly efficiency and clinician/admin productivity, not AI revenue. Management offers one hard metric (roughly 2x Conifer analytics productivity) and ties AI/automation broadly to offsetting operating headwinds, but rebuffs the industry narrative of AI-driven aggressive coding uplift. Credibility is moderate: specific use cases and governance are credible; financial attribution to AI remains largely qualitative and pilot-stage outside the Conifer analytics claim.
GROUNDED NEXT-FY IMPACT vs CONSENSUS
Grounded on actual base — revenue $21.3B · net income $1.4B · net margin 6.6% · diluted EPS 15.49
These are next-fiscal-year annual uplift estimates, not next-quarter numbers.
Aggregate next-FY est. rev uplift: % · next-FY EPS uplift: % · vs analysts: unclear · priced in: medium (model's call-read: high; verdict above is the hard-data one used for ranking) · confidence: 2/10
| Claim | Figure | Arithmetic | Next-FY Rev % | Next-FY EPS % |
|---|
Conifer analytics team productivity almost doubled
productivity · soft | ~+100% ("almost doubled or more") productivity of the Conifer analytics team | 2x productivity => ~50% labor-equivalent savings on undisclosed Conifer analytics opex. No team headcount, labor cost, or dollar base is disclosed anywhere in management's claims, so saving_$ is unknown and eps_uplift_pct cannot be computed: after_tax_saving=saving_$*0.79; eps_uplift_pct=100*after_tax_saving/1,407,000,000 => null. Back-office efficiency with no monetized capacity => rev_uplift_pct=0. Order-of-magnitude bound only: a plausible $5-30M pretax -> $4-24M after-tax is just 0.3-1.7% of $1,407M NI, immaterial vs the $21.3B revenue base. | 0 | |
Assumptions: Productivity interpreted as ~2x output per FTE (~50% cost reduction at flat volume). Tax rate 21% on any savings; incremental net margin N/A (no revenue claim). No revenue phasing — the gain is cited as already realized. EPS basis: consensus uses adjusted EPS (~$16.09 FY2025 -> ~$17.88 FY2026); GAAP FY2025 EPS used only as NI cross-check ($1.407B). Conifer analytics team opex is not disclosed in any provided claim, so the saving cannot be sized without inventing a base -> treated as unanchored (soft). Forward statements ("piloting agentic workflows", "prepared for the years ahead", "next level of improvement") are qualitative and carry no figures.
Top line: No topline impact. The sole quantified AI outcome is a back-office productivity gain (Conifer analytics team), a cost/efficiency item with no disclosed revenue/bookings or volume-capacity monetization. THC is an AI adopter, not a supplier; there is no AI-driven revenue line to size against the $21.31B base. rev_uplift_pct=0.
Bottom line: Bottom-line only, and unsizable from the disclosures. "Almost doubling" the productivity of one Conifer analytics sub-team has no disclosed labor/cost base, so no defensible consolidated EPS uplift can be computed (est_eps_uplift_pct=null). A generous bound ($5-30M pretax -> $4-24M after-tax) is only 0.3-1.7% of $1,407M NI, and the realistic figure is well below that — immaterial against a $21.3B/$1.4B base.
[impact n/m (all claims soft/unanchored)] Only hard claim is subsidiary-level productivity with no $ anchor. Consensus already embeds ~11% FY26 EPS growth (16.09 -> 17.88) and ~11.6% NI growth ($1,462M -> $1,631M) with no AI line item to point to. Even the most aggressive bound (~$24M after-tax, ~1.7% of NI) is a fraction of the ~$169M NI step-up consensus already assumes, and the likely figure is far smaller. No computable adopter EPS uplift points above consensus, so any benefit is comfortably inside what is already priced.
MODEL CONSENSUS (impact)
partial
Agree on adopter, soft, null EPS, high priced_in, unclear vs expectations; reconciled rev pcts to 0 and confidence down to 2.
Conflicts reconciled
- rev_uplift_pct: X=null vs Y=0 -> used 0 because a back-office productivity gain has a definite ~0 topline per method (Topline ~0), not an unknown
- est_rev_uplift_pct: X=null vs Y=0 -> used 0 for the same reason (no revenue claims at all)
- confidence: X=3 vs Y=2 -> used 2, the more conservative value given the unsizable, unanchored sole claim
| Field | Opus 4.8 | GPT-5.5 |
|---|
| Rev uplift % | – | – |
| EPS uplift % | – | – |
| Priced in | high | – |
| vs analysts | unclear | – |
| Confidence | 3 | – |
| Top line | No topline impact. The only quantified AI claim is a back-office productivity gain (Conifer analytics team), which is a cost/efficiency item, not revenue. THC is an AI adopter, not a supplier; there is no AI-driven revenue line to size against the $21.31B base. | – |
| Bottom line | Bottom-line only, and unsizable from the disclosures. "Almost doubling" the productivity of one analytics sub-team within Conifer has no disclosed labor/cost base, so no defensible EPS uplift can be computed. A generous bound ($5-30M pretax -> $4-24M after-tax) is just 0.3-1.7% of $1,407M net income, and the realistic figure is well below that — immaterial against a $21.3B/$1.4B base. Set to null rather than manufacture a denominator. | – |
| Reasoning | Consensus already embeds ~11% FY26 EPS growth (16.09 -> 17.88) and ~11.6% net-income growth ($1,462M -> $1,631M) with no AI line item to point to. The single quantified AI claim is a sub-team productivity gain with no dollar base; even its most aggressive bound (~$24M after-tax, ~1.7% of NI) is a fraction of the ~$169M NI step-up consensus already assumes, and the likely figure is far smaller. There is no math that points above consensus, so any benefit is comfortably inside what is already priced. | – |
Rows highlighted where the two models disagreed.
QUANTIFICATIONS
Conifer analytics team productivity: almost doubled or more (current (cited in Q1 FY2026 prepared remarks as realized outcome of back-office AI automation), bottomline)
“For example, we have almost doubled or more the productivity of our Conifer analytics team.”
PAST (realized)
- Q1 FY2026 — Saumya Sutaria: "For example, we have almost doubled or more the productivity of our Conifer analytics team."
- Q1 FY2026 — Saumya Sutaria: "most of which have been useful for supporting extending the productivity metrics of our team."
- Q1 FY2026 — Saumya Sutaria: "So far, our work has enabled us to more than offset the expected and unexpected headwinds that arose in the quarter."
CURRENT (now)
- Q1 FY2026 — Saumya Sutaria: "we are executing on AI-related capabilities in our hospitals, physician practices and the global business center to drive further efficiencies"
- Q1 FY2026 — Saumya Sutaria: "setting up a governance that either green lights for rapid scaling up or red lights for shutdown"
- Q1 FY2026 — Saumya Sutaria: "ambient scribe, automated discharge summaries and autonomous professional fee coding in various pilot programs"
- Q1 FY2026 — Saumya Sutaria: "we have increased back-office AI automation, which is improving productivity and consolidating third-party spend to reduce costs"
- Q1 FY2026 — Saumya Sutaria: "some of these new tools that we're trying out are helping to add to our more traditional length of stay management"
- Q4 FY2025 — Saumya Sutaria: "application of those technologies in our global business center" and clinical-throughput technology "ramping up"
FORWARD (guidance)
- Q1 FY2026 — Saumya Sutaria: "we are actively identifying and piloting agentic workflows to transform further business processes"
- Q4 FY2025 — Saumya Sutaria: expense/technology initiatives are "not just about 2026, it's about being prepared for the years ahead"
- Q4 FY2025 — Saumya Sutaria: "the ability to actually begin to deploy" AI and automation "and see if we can drive the next level of improvement"
TRACK RECORD — PROMISE vs DELIVERY
—/100 (no quantified promises) no-quantified-promises 6 calls reviewed
From Q4 FY2024 through Q1 FY2026, Tenet discussed AI, automation, advanced analytics, and revenue-cycle technology only qualitatively or as pilots and realized gains (e.g., ~2x Conifer analytics productivity in Q1 FY2026), without any AI-related commitment that combined a numeric target and a deadline, so promise-versus-delivery credibility cannot be scored.
PRICED-IN (REFINED)
MEDIUMEst. revisions flat · Fwd P/E 14.5 · EV/Sales 1.1x
AI claim maps to Hospital Operations, Ambulatory Care
Analyst ratings improved modestly (strong buys 5→6, holds 3→2) but near-term price targets fell (lastMonthAvg 236 vs lastQuarterAvg 249), so revision momentum is mixed rather than clearly rising. Forward consensus already embeds a steep EPS path ($11.32→$16.09→$17.88) while revenue growth stays low-single-digit, suggesting much operational upside is in the numbers even if AI is not labeled. Valuation is not stretched (14.5x next-FY P/E, ~1.1x EV/Sales), which limits a “high” verdict, but the combination of bullish crowding, baked-in EPS growth, and flat/conflicting revisions supports medium priced-in for AI-driven upside.
COVERAGE — ENTHUSIASM TRAJECTORY + CATALYSTS
2Q4 FY20242Q1 FY20253Q2 FY20253Q3 FY20253Q4 FY20257Q1 FY2026
AI enthusiasm across 6 calls — trend ↗ rising
Five quarters of ops focus only; Q1 FY2026 added explicit AI pilots, governance, and Conifer productivity gains.
RECENT AI CATALYSTS & NEWS
BUSINESS IMPACT - QUALITATIVE MATERIALITY
5/10 qualitative impact moderate medium-term · mixed evidence
Where AI matters: clinical/admin productivity and RCM cost efficiency
Tenet is a credible adopter—ambient scribe, discharge summaries, fee coding pilots, back-office automation, and ~2x Conifer analytics productivity—but disclosures show efficiency/offset of headwinds, not AI revenue or sizable consolidated EPS, with most impact still pilot-stage and unquantified at scale.
Caveats: Financial benefit largely qualitative with only one subsidiary productivity metric and no $/EPS bridge; Most clinical AI tools still in pilot with governance-driven scale-or-shutdown risk; Payer AI on denials/underpayments can pressure net revenue even as Tenet adopts AI for efficiency; Conifer/third-party RCM could face commoditization if AI standardizes analytics services
AI DISRUPTION / CANNIBALIZATION RISK tailwind · 3/10
Core economics remain tied to licensed in-person acute/ambulatory care that AI does not replace; AI mainly automates documentation, coding, and back-office work Tenet already wants cheaper, while payer-side AI tightening denials is a partial RCM headwind management explicitly does not offset via aggressive AI coding uplift.
OPTIONS / MARKET STRUCTURE
option liquidity: fair
proxy inputs — dollar-ADV $219M · beta 1.299 · px $163.60
source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.
CONFIRMATION — INSIDERS · 13F · LANGUAGE
Mixed — insiders selling, institutions adding, management language 5/10 measured.
INSIDERS selling 12 open-market sell(s) vs 0 buy(s) — net distribution
INSTITUTIONS (13F) adding as of 2026-03-31: 101 new / 114 closed positions; 333 increased / 277 reduced; institutional ownership -5.89pp; -18 net 13F holders
MGMT LANGUAGE 5/10 measured Brief AI section: firm back-office execution with a productivity metric, but clinical AI and agentic work stay pilot-focused with no rollout timelines.
commit “we are executing on AI-related capabilities in our hospitals, physician practices and the global business center to drive further efficiencies”
commit “we have almost doubled or more the productivity of our Conifer analytics team”
hedge “ambient scribe, automated discharge summaries and autonomous professional fee coding in various pilot programs”
VERBATIM AI QUOTES
“Among these things, we are executing on AI-related capabilities in our hospitals, physician practices and the global business center to drive further efficiencies, most of which have been useful for supporting extending the productivity metrics of our team.”
— Saumya Sutaria, Q1 FY2026
“Importantly, we have learned that while all of these tools will not work in a pilot state, setting up a governance that either green lights for rapid scaling up or red lights for shutdown help us remain focused.”
— Saumya Sutaria, Q1 FY2026
“We have included third-party EMR integrated solutions with -- which will increase our clinician productivity, decrease administrative burden and improve patient access through programs such as ambient scribe, automated discharge summaries and autonomous professional fee coding in various pilot programs.”
— Saumya Sutaria, Q1 FY2026
“Additionally, we have increased back-office AI automation, which is improving productivity and consolidating third-party spend to reduce costs.”
— Saumya Sutaria, Q1 FY2026
“For example, we have almost doubled or more the productivity of our Conifer analytics team.”
— Saumya Sutaria, Q1 FY2026
“As we look forward, we are actively identifying and piloting agentic workflows to transform further business processes.”
— Saumya Sutaria, Q1 FY2026
“So far, our work has enabled us to more than offset the expected and unexpected headwinds that arose in the quarter.”
— Saumya Sutaria, Q1 FY2026
“when you look at the opportunity to find efficiencies, you look at the support services for the hospitals, and you look at some of the automation opportunities that I described.”
— Saumya Sutaria, Q1 FY2026
“we're pleased that some of these new tools that we're trying out are helping to add to our more traditional length of stay management that we've talked about over the last 4 or 5 years.”
— Saumya Sutaria, Q1 FY2026
“We're looking, as we've talked about over the past year, more thoroughly at the deployment of technology, basically that allows us more expense reduction opportunities, and that includes application of those technologies in our global business center.”
— Saumya Sutaria, Q4 FY2025
“It's not just AI, which has, I think, become kind of the central buzzword for this, but there's a lot more that can be done in automation.”
— Saumya Sutaria, Q4 FY2025
“And then the other thing is just as we look at our clinical throughput, application of those technologies ramping up in our clinical throughput, we believe, is another area to take things to the next level.”
— Saumya Sutaria, Q4 FY2025
“So whether that's areas like length of stay management or throughput in some of the more high-value portions of the hospitals, real estate, et cetera, ORs, ERs, et cetera. Those kinds of things become more structural in nature.”
— Saumya Sutaria, Q4 FY2025
“And now with the advent of many of these technologies in AI and automation, the ability to actually begin to deploy those and see if we can drive the next level of improvement, we're better set up for that now because we have more standard processes.”
— Saumya Sutaria, Q4 FY2025
“Our coding has always been appropriate, compliant. It's -- we audit carefully. We haven't changed our coding practices over the last few years, either for ourselves or necessarily for our clients.”
— Saumya Sutaria, Q4 FY2025
ANALYST QUESTIONS ON AI
Q (Q4 FY2025, Benjamin Mayo (Leerink Partners)): When you say, Saum, that you're tackling expense management more structurally, what do you mean by that? And can you elaborate on what's incremental about the cost efficiencies that you expect to see this year?
A: Saumya Sutaria described a shift from traditional annual expense management to broader technology deployment for expense reduction, including in the global business center; said it is "not just AI, which has, I think, become kind of the central buzzword for this, but there's a lot more that can be done in automation," and that ramping technologies in clinical throughput (e.g., length of stay, ORs, ERs) is a more structural next level.
Q (Q4 FY2025, Joshua Raskin (Nephron Research)): I'd just be curious to get your view on just the broader technology agenda, specifically, including AI and overall business, including revenue cycle management. And just do you think there's additional step function improvements in margins.
A: Saumya Sutaria said margin expansion opportunity remains in hospitals absent exchange headwinds; argued Tenet is better set up now with standard processes, workflows, and labor/supply standards to deploy "many of these technologies in AI and automation" for the next level of improvement.
Q (Q4 FY2025, John Ransom (Raymond James)): There's a big narrative over the past few months that providers are getting on top of payers with coding advances assisted by AI, particularly claims resubmissions are easier. Is that exaggerated? What inning are we in? And just given that you're positioned owning Conifer and being a provider, what's your position on that debate?
A: Saumya Sutaria said Tenet/Conifer coding has always been appropriate and compliant, audited carefully, and "We haven't changed our coding practices over the last few years"; attributed net revenue per case gains to acuity, not AI-driven coding changes; said disputes center on denials/underpayments, with efforts to set up less resource-intensive adjudication with plans.
Q (Q1 FY2026, Jason Cassorla (Guggenheim Partners)): Could you just double a little bit more on the length of stay opportunity for you and what that run rate looks like as you move through the rest of the year and beyond?
A: Saumya Sutaria linked throughput/LOS management to high-acuity strategy and capital avoidance, and said "some of these new tools that we're trying out are helping to add to our more traditional length of stay management."
Q (Q1 FY2026, Albert Rice (UBS)): Are there some markets where you've implemented strategies that you'd call out that have been particularly successful... And as you look across the portfolio, maybe discuss some markets that still have an opportunity for significant improvement as you deploy new strategies to improve their performance.
A: Saumya Sutaria said efficiency and "automation opportunities that I described" are available in each market, scaled by market size; credited Q1 hospital earnings partly to consistency across markets on those efficiency opportunities plus cost flexing.